Abstract:Journal of Psychopharmacology, Ahead of Print. Background:There is high inter-individual variability in clozapine metabolism due to genetic and non-genetic differences. Patient-specific factors such as smoking, inflammation indicated by elevated C-reactive protein (CRP), and certain concurrent medications have a significant influence on clozapine metabolism.Aim:To assess which patient-specific factors best explain variability in clozapine metabolism estimated by clozapine concentration to dose (C/D) ratios.Methods:A retrospective cohort analysis using electronic medical data was conducted on 172 inpatients at the BC Psychosis Program. Patients with normal renal and liver function were included if they were on clozapine and had at least one steady-state plasma concentration. The degree of influence of each factor on the variability of clozapine metabolism in the entire cohort and subgroups stratified by fluvoxamine use was evaluated using multiple linear regression analysis of C/D ratios.Results:Model fit testing showed that the entire cohort model accounts for 52.7% of C/D ratio variability, while the no fluvoxamine and fluvoxamine models accounted for 40.8% and 43.8%. In the entire cohort (n = 172), fluvoxamine use explained the highest variance, and C/D ratios were higher by 30.6% on average. The second strongest predictor was elevated CRP > 10 mg/L, and C/D ratios were higher by 22.9% on average. Subsequently, obesity, nonsmoker status, and female sex explained a significant but modest proportion of variance. Among participants on fluvoxamine (n = 58), only fluvoxamine dose was associated with an increase, and for every 25 mg increase in dose, C/D ratios increased by 5% on average.Conclusion:In a clinical population, this study replicated the relationship between reduced rate of clozapine metabolism and the use of fluvoxamine, elevated CRP, obesity, nonsmoking status, and female sex; and the magnitude of the effects were large enough to be clinically relevant.

Metabolic Syndrome in Patients Taking Clozapine: Prevalence and Influence of Catechol-O-methyltransferase Genotype

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

Association Study Of Val66met Polymorphism In Brain-Derived Neurotrophic Factor Gene With Clozapine-Induced Metabolic Syndrome: Preliminary Results

The inconsistent mediating effect of catechol O methyl transferase Val158Met polymorphism on the sex difference of cognitive impairment in schizophrenia patients

Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis

Morphological Changes in Gray Matter Volume Correlate with Catechol-O-methyl Transferase Gene Val158Met Polymorphism in First-Episode Treatment-Naïve Patients with Schizophrenia

Genetic Polymorphism in Catechol‐o‐methyltransferase Associated with the Functional Connectivity of Frontostriatal Circuits in First Episode Schizophrenia Patients

Genetic Contribution of Catechol-O-methyltransferase in Dorsolateral Prefrontal Cortex Functional Changes in the First Episode Schizophrenia

Association Between the COMT Val158Met Polymorphism and Antipsychotic Efficacy in Schizophrenia: an Updated Meta-Analysis.

Impact of clozapine monotherapy on gut microbiota and metabolism in people with schizophrenia

Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Association of Catechol-O-methyltransferase Val(108/158) Met Genetic Polymorphism with Schizophrenia, P50 Sensory Gating, and Negative Symptoms in a Chinese Population.

Increased risk of atypical antipsychotics-induced metabolic syndrome associated with MIF CATT >5/6 among females with chronic schizophrenia

Association between SREBF2 gene polymorphisms and metabolic syndrome in clozapine-treated patients with schizophrenia.

Association Betweenscapandsrebf1gene Polymorphisms and Metabolic Syndrome in Schizophrenia Patients Treated with Atypical Antipsychotics

Catechol-O-methyltransferase (COMT) single nucleotide polymorphisms and haplotypes are not major risk factors for polycystic ovary syndrome

Further evidence of transmission disequilibrium of the catechol-O-methyl transferase (COMT) gene in schizophrenia in a Chinese population

Clozapine causes oxidation of proteins involved in energy metabolism: a possible mechanism for antipsychotic-induced metabolic alterations

Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder

Association Between Catechol-O-methyltransferase Genetic Variation and Functional Connectivity in Patients with First-Episode Schizophrenia